These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 31509718)

  • 1. When Should Tumor Genomic Profiling Prompt Consideration of Germline Testing?
    DeLeonardis K; Hogan L; Cannistra SA; Rangachari D; Tung N
    J Oncol Pract; 2019 Sep; 15(9):465-473. PubMed ID: 31509718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Somatic" Tumor Genomic Profiling and Potential Germline Implications: Ethical Considerations for Children with Cancer.
    Knapp E
    J Law Med Ethics; 2020 Dec; 48(4):778-783. PubMed ID: 33404327
    [No Abstract]   [Full Text] [Related]  

  • 3. Integrating next-generation sequencing into pediatric oncology practice: An assessment of physician confidence and understanding of clinical genomics.
    Johnson LM; Valdez JM; Quinn EA; Sykes AD; McGee RB; Nuccio R; Hines-Dowell SJ; Baker JN; Kesserwan C; Nichols KE; Mandrell BN
    Cancer; 2017 Jun; 123(12):2352-2359. PubMed ID: 28192596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-Based Genetic Testing and Familial Cancer Risk.
    Forman A; Sotelo J
    Cold Spring Harb Perspect Med; 2020 Aug; 10(8):. PubMed ID: 31570381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of clinically relevant germline variants detected by next-generation sequencing in patients with childhood cancer: a review of the literature.
    Sylvester DE; Chen Y; Jamieson RV; Dalla-Pozza L; Byrne JA
    J Med Genet; 2018 Dec; 55(12):785-793. PubMed ID: 30287599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germline Analysis from Tumor-Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings.
    Seifert BA; O'Daniel JM; Amin K; Marchuk DS; Patel NM; Parker JS; Hoyle AP; Mose LE; Marron A; Hayward MC; Bizon C; Wilhelmsen KC; Evans JP; Earp HS; Sharpless NE; Hayes DN; Berg JS
    Clin Cancer Res; 2016 Aug; 22(16):4087-4094. PubMed ID: 27083775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substantial batch effects in TCGA exome sequences undermine pan-cancer analysis of germline variants.
    Rasnic R; Brandes N; Zuk O; Linial M
    BMC Cancer; 2019 Aug; 19(1):783. PubMed ID: 31391007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in phase I clinical trials.
    McVeigh TP; Sundar R; Diamantis N; Kaye SB; Banerji U; Lopez JS; de Bono J; van der Graaf WTA; George AJ
    Eur J Cancer; 2018 May; 95():20-29. PubMed ID: 29614442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility.
    Robson ME; Bradbury AR; Arun B; Domchek SM; Ford JM; Hampel HL; Lipkin SM; Syngal S; Wollins DS; Lindor NM
    J Clin Oncol; 2015 Nov; 33(31):3660-7. PubMed ID: 26324357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol.
    Meric-Bernstam F; Brusco L; Daniels M; Wathoo C; Bailey AM; Strong L; Shaw K; Lu K; Qi Y; Zhao H; Lara-Guerra H; Litton J; Arun B; Eterovic AK; Aytac U; Routbort M; Subbiah V; Janku F; Davies MA; Kopetz S; Mendelsohn J; Mills GB; Chen K
    Ann Oncol; 2016 May; 27(5):795-800. PubMed ID: 26787237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline mutations and new copy number variants among 40 pediatric cancer patients suspected for genetic predisposition.
    Gambale A; Russo R; Andolfo I; Quaglietta L; De Rosa G; Contestabile V; De Martino L; Genesio R; Pignataro P; Giglio S; Capasso M; Parasole R; Pasini B; Iolascon A
    Clin Genet; 2019 Oct; 96(4):359-365. PubMed ID: 31278746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline, hematopoietic, mosaic, and somatic variation: interplay between inherited and acquired genetic alterations in disease assessment.
    Konnick EQ; Pritchard CC
    Genome Med; 2016 Oct; 8(1):100. PubMed ID: 27716394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.
    Mandelker D; Zhang L; Kemel Y; Stadler ZK; Joseph V; Zehir A; Pradhan N; Arnold A; Walsh MF; Li Y; Balakrishnan AR; Syed A; Prasad M; Nafa K; Carlo MI; Cadoo KA; Sheehan M; Fleischut MH; Salo-Mullen E; Trottier M; Lipkin SM; Lincoln A; Mukherjee S; Ravichandran V; Cambria R; Galle J; Abida W; Arcila ME; Benayed R; Shah R; Yu K; Bajorin DF; Coleman JA; Leach SD; Lowery MA; Garcia-Aguilar J; Kantoff PW; Sawyers CL; Dickler MN; Saltz L; Motzer RJ; O'Reilly EM; Scher HI; Baselga J; Klimstra DS; Solit DB; Hyman DM; Berger MF; Ladanyi M; Robson ME; Offit K
    JAMA; 2017 Sep; 318(9):825-835. PubMed ID: 28873162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discrepancies between tumor genomic profiling and germline genetic testing.
    Pauley K; Koptiuch C; Greenberg S; Kohlmann W; Jeter J; Colonna S; Werner T; Kinsey C; Gilcrease G; Weis J; Whisenant J; Florou V; Garrido-Laguna I
    ESMO Open; 2022 Aug; 7(4):100526. PubMed ID: 35780590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cascade testing for hereditary cancer: comprehensive multigene panels identify unexpected actionable findings in relatives.
    Heald B; Pirzadeh-Miller S; Ellsworth RE; Nielsen SM; Russell EM; Beitsch P; Esplin ED; Nussbaum RL; Pineda-Alvarez DE; Kurian AW; Hampel H
    J Natl Cancer Inst; 2024 Feb; 116(2):334-337. PubMed ID: 37756683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toward Concurrent Testing for Somatic and Germline Variants in Cancer Patients.
    Mandelker D
    Clin Cancer Res; 2016 Aug; 22(16):3987-8. PubMed ID: 27307597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric cancer genetics.
    Dean SJ; Farmer M
    Curr Opin Pediatr; 2017 Dec; 29(6):629-633. PubMed ID: 28984800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline potential should not be overlooked for cancer variants identified in tumour-only somatic mutation testing.
    Al-Shinnag M; Cheong PL; Goodwin A; Trent R; Yu B
    Pathology; 2024 Jun; 56(4):468-472. PubMed ID: 38627125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer Predisposition Sequencing Reporter (CPSR): A flexible variant report engine for high-throughput germline screening in cancer.
    Nakken S; Saveliev V; Hofmann O; Møller P; Myklebost O; Hovig E
    Int J Cancer; 2021 Dec; 149(11):1955-1960. PubMed ID: 34310709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.